Low and conventional dose cyclopenthiazide on glucose and lipid metabolism in mild hypertension.

Abstract

In a double-blind, placebo controlled, randomised parallel study we investigated the antihypertensive activity and metabolic adverse effects of three doses of cyclopenthiazide in 53 patients with mild hypertension. After a 4 week placebo washout period, patients with diastolic blood pressures between 90-110 mm Hg were randomly assigned to receive 50 micrograms, 125 micrograms and 500 micrograms of cyclopenthiazide or matching placebo, over an 8 week active treatment period. Blood pressure was recorded at 2 weekly intervals during the trial. Venous samples were taken for evaluation of drug effect on indices of carbohydrate and lipid metabolism just prior to, and on completion of, the active treatment period. Systolic and diastolic blood pressure decreased significantly (P less than 0.05) with the 125 micrograms and 500 micrograms doses of cyclopenthiazide. No change was apparent in any index of glucose and lipid metabolism over time. Low and conventional doses of cyclopenthiazide lower blood pressure without alteration to the metabolic profile in the short term.

• Authors: G E McVeigh, E B Dulie, A Ravenscroft, D B Galloway, G D Johnston
• Journal: British journal of clinical pharmacology (Br J Clin Pharmacol) Vol. 27 Issue 4 Pg. 523-6 (Apr 1989) ISSN: 0306-5251 [Print] England
• PMID: 2655692 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)

Chemical References

• Apoproteins
• Blood Glucose
• Diuretics
• Glycated Hemoglobin A
• Insulin
• Lipids
• Lipoproteins
• Sodium Chloride Symporter Inhibitors
• Cyclopenthiazide

Topics

• Apoproteins (blood)
• Blood Glucose (metabolism)
• Blood Pressure (drug effects)
• Clinical Trials as Topic
• Cyclopenthiazide (therapeutic use)
• Diuretics
• Double-Blind Method
• Glycated Hemoglobin (metabolism)
• Humans
• Hypertension (blood, drug therapy, physiopathology)
• Insulin (blood)
• Lipids (blood)
• Lipoproteins (blood)
• Random Allocation
• Sodium Chloride Symporter Inhibitors (therapeutic use)